• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VBS
Click for more information
0.00% 8.0¢

VECTUS BIOSYSTEMS LIMITED - Announcements

Market Cap $4.256M  ! watchlist Created with Sketch. Add to my watchlist

Vectus Biosystems Limited is an Australia-based drug discovery and development company.... Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
VBS Half Year Report and Appendix 4DPRICE SENSITIVE28/02/19
VBS Response to ASX Appendix 4C QueryPRICE SENSITIVE22/02/19
VBS Appendix 4C - Quarterly ReportPRICE SENSITIVE31/01/19
VBS CEO's Address to ShareholdersPRICE SENSITIVE14/11/18
VBS Chairman's Address to ShareholdersPRICE SENSITIVE14/11/18
VBS Appendix 4C - quarterlyPRICE SENSITIVE31/10/18
VBS Preliminary Final ReportPRICE SENSITIVE31/08/18
VBS Appendix 4C - quarterlyPRICE SENSITIVE31/07/18
VBS Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
VBS Half Year Report and Appendix 4DPRICE SENSITIVE28/02/18
VBS Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
VBS Appendix 4C - QuarterlyPRICE SENSITIVE31/10/17
VBS Successful Pre-Clinical Trial and Granting of Key PatentPRICE SENSITIVE20/10/17
VBS Preliminary Final ReportPRICE SENSITIVE31/08/17
VBS Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
VBS Appendix 4C - Quarterly Report and UpdatePRICE SENSITIVE28/04/17
VBS Half Yearly Report and Appendix 4DPRICE SENSITIVE28/02/17
VBS Response to ASX Appendix 4C QueryPRICE SENSITIVE13/02/17
VBS Appendix 4C - quarterlyPRICE SENSITIVE30/01/17
VBS Response to ASX Appendix 4C QueryPRICE SENSITIVE14/11/16
VBS Appendix 4C - quarterly-VBS.AX PRICE SENSITIVE31/10/16
VBS Preliminary Final Report-VBS.AX PRICE SENSITIVE31/08/16
VBS Appendix 4C - quarterly-VBS.AX PRICE SENSITIVE29/07/16
VBS Appendix 4C - quarterly-VBS.AX PRICE SENSITIVE29/04/16
VBS Scientific Paper on Accugen TechnologyPRICE SENSITIVE15/03/16
VBS Key Accugen Patent Granted in USAPRICE SENSITIVE07/03/16
VBS Admission to Official ListPRICE SENSITIVE22/02/16
VBS Half Year Report and Appendix 4D
28/02/19PRICE SENSITIVE
VBS Response to ASX Appendix 4C Query
22/02/19PRICE SENSITIVE
VBS Appendix 4C - Quarterly Report
31/01/19PRICE SENSITIVE
VBS CEO's Address to Shareholders
14/11/18PRICE SENSITIVE
VBS Chairman's Address to Shareholders
14/11/18PRICE SENSITIVE
VBS Appendix 4C - quarterly
31/10/18PRICE SENSITIVE
VBS Preliminary Final Report
31/08/18PRICE SENSITIVE
VBS Appendix 4C - quarterly
31/07/18PRICE SENSITIVE
VBS Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
VBS Half Year Report and Appendix 4D
28/02/18PRICE SENSITIVE
VBS Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
VBS Appendix 4C - Quarterly
31/10/17PRICE SENSITIVE
VBS Successful Pre-Clinical Trial and Granting of Key Patent
20/10/17PRICE SENSITIVE
VBS Preliminary Final Report
31/08/17PRICE SENSITIVE
VBS Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
VBS Appendix 4C - Quarterly Report and Update
28/04/17PRICE SENSITIVE
VBS Half Yearly Report and Appendix 4D
28/02/17PRICE SENSITIVE
VBS Response to ASX Appendix 4C Query
13/02/17PRICE SENSITIVE
VBS Appendix 4C - quarterly
30/01/17PRICE SENSITIVE
VBS Response to ASX Appendix 4C Query
14/11/16PRICE SENSITIVE
VBS Appendix 4C - quarterly-VBS.AX
31/10/16PRICE SENSITIVE
VBS Preliminary Final Report-VBS.AX
31/08/16PRICE SENSITIVE
VBS Appendix 4C - quarterly-VBS.AX
29/07/16PRICE SENSITIVE
VBS Appendix 4C - quarterly-VBS.AX
29/04/16PRICE SENSITIVE
VBS Scientific Paper on Accugen Technology
15/03/16PRICE SENSITIVE
VBS Key Accugen Patent Granted in USA
07/03/16PRICE SENSITIVE
VBS Admission to Official List
22/02/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
8.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $4.256M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 68000 7.8¢
 

Sellers (Offers)

Price($) Vol. No.
11.5¢ 6250 1
View Market Depth
Last trade - 16.12pm 22/11/2024 (20 minute delay) ?
VBS (ASX) Chart

Top Stories

iTech inks deal with Chilean lithium giant to progress Reynolds Range

iTech Minerals Ltd has signed a deal which will allow for the development of its Reynolds Range lithium project
HotCopper users react as Pancontinental Energy's trading halt lift reveals little Pancontinental has lifted a trading halt to reveal its hotly awaited potential deal with Woodside is...still just potential.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.